GNRH1

DUBLIN--( BUSINESS WIRE )--The "United States Endometriosis and Uterine Fibroids Market (2024 Edition): Analysis By Drug Type, By Route of Administration, By Distribution Channel, By Region, By Country: Market Insights and Forecast (2020-2030)" report has been added to ResearchAndMarkets.com's offering. The United States Endometriosis and Uterine Fibroids Market showcased growth at a CAGR of 4.09% during 2020-2023. The market was valued at USD 415.70 Million in 2023 which is expected to reach USD 568.07 Million in 2030. The research report provides a complete analysis for the historical period of 2020-2023, the estimates of 2024 and the forecast period of 2025-2030. The United States has been experiencing a significant boom in recent years, driven by growing prevalence of the disease due to technological advancements in the diagnostics techniques in the United States, increased awareness towards reproductive disorders, and increased expenditure of capital in the Research and Development organizations in the United States. Due to the limited number of drugs available for the treatment of Endometriosis and Uterine Fibroids, it becomes imperative to find novel treatment outcomes for enhancing the quality of life of the patients. Surgical removal of the fibroids is the only effective treatment option available for treating the disease. However, many females prefer drug therapies over surgical procedures as they are non-invasive. Endometriosis, on the other hand not only affects the uterus but, it also spreads to other reproductive organs, if not treated properly. Increased investments by pharmaceutical companies on exploring the efficacy of different classes of hormonal drugs can pave way for a new drug in the market through different routes of administration such as oral, and parenteral. The emergence of newer technologies such as nanocarrier delivery of drugs, skin patches for epidermal drug delivery have increased the preference for drug therapies in the United States. The landscape of drug development in United States has changed dramatically. Precision medicine has emerged as a result of the elimination of conventional treatment options available for endometriosis and uterine fibroids. Clinicians can prescribe medications based on the clinical presentation, genetic profile, and the severity or stage of endometriosis. Scientists have focused their research on developing tailored medicines for the treatment of endometriosis and uterine fibroids by utilising high resolution omics data and meta-analysis of disease profile. New avenues in the research and development for endometriosis and uterine fibroids treatment have been made possible by incorporating artificial intelligence and machine learning in drug manufacturing processes. Various distribution channels such as Hospital pharmacies, retail pharmacies or online pharmacies offers widespread delivery of medicine to the consumers especially for those living in remote areas or facing time constraints. In the coming years, the online channels have the potential to elevate the market sales of drugs. Furthermore, the use of biodegradable implants for delivering hormonal drugs such as progesterone, Gonadotrophin releasing hormone agonists, and Gonadotrophin releasing agonists is one of the trends in the United States endometriosis and uterine fibroid market. These biodegradable implants are biocompatible and non-invasive in nature. In addition to these benefits, drug implants consume less time and can be implemented in the case of controlling the symptoms associated with the diseases. Scope of the Report The report analyses the Global, Americas and United States Endometriosis and Uterine Fibroids Market by Value (USD Million). The report includes a detailed assessment of United States Endometriosis and Uterine Fibroids Market by Value (USD Million). The report analyses the United States Endometriosis and Uterine Fibroids Market by Epidemiology. The report analyses the United States Endometriosis and Uterine Fibroids Market by Pipeline Scenario. The report presents the analysis of United States Endometriosis and Uterine Fibroids Market for the historical period of 2020-2023, the estimated year 2024, and the forecast period of 2025-2030. The report analyses the United States Endometriosis and Uterine Fibroids Market, By Drug Type (GnRH Antagonists, Progesterone, GnRh Agonist and Others). The report analyses the United States Endometriosis and Uterine Fibroids Market By Route of Administration (Oral and Parenteral). The report analyses the United States Endometriosis and Uterine Fibroids Market By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies). The key insights of the report have been presented through the frameworks of SWOT and Porter's Five Forces Analysis. Also, the attractiveness of the market has been presented By Drug Type, by Route of Administration & by Distribution Channel. Also, the major opportunities, trends, drivers, and challenges of the industry has been analyzed in the report. The report tracks competitive developments, strategies, mergers and acquisitions and new Drug development. Analyst Recommendations Augment the availability of combinational drugs Escalate Distribution through Online services Competitive Positioning Companies Product Positioning Market Position Matrix Market Share Analysis of United States Endometriosis and Uterine Fibroids Market Company Profiles AbbVie Inc. Pfizer Inc. AstraZeneca plc. Tolmar Inc. Glenmark Pharmaceuticals Ltd. Aspen Pharmacare Holdings Ltd. Agile Therapeutics Inc Medicines 360 Cipla Ltd Takeda Pharmaceuticals For more information about this report visit https://www.researchandmarkets.com/r/giumio About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Sirnaomics, a company that has been deeply involved in the peptide field for over 20 years, achieved significant growth in the export of peptide APIs in the first half of the year, with a year-on-year growth rate of 97.51%, showing its strong development momentum. Although the company experienced violent fluctuations in the capital market, its profound accumulation in the peptide field and stable performance growth have made it an important force in the industry.   Sirnaomics' three core businesses - innovative drug CDMO services for peptides, peptide formulations business, and peptide API business - have collectively driven growth in performance. Of these, the API business has performed particularly well, with overseas sales growing by 97.51% year-on-year, becoming one of the main driving forces for profit growth.   Peptide drugs are a type of emerging drugs that lie between small molecule chemical drugs and protein drugs, with advantages such as high activity, low toxicity, and quality control. They are suitable for solving complex diseases that are difficult to address with small molecule chemical drugs.   The global peptide drug market size has already exceeded $20 billion, accounting for about 2% of the total pharmaceutical market, but it has maintained a high growth rate of around 10%. Some of the most popular peptide drugs include GLP-1 analogues, used to treat type 2 diabetes, such as liraglutide and exenatide, with sales exceeding $3 billion. Growth hormone and growth hormone-like substances are used to treat diseases caused by disorders in growth hormone secretion, with global sales of approximately $2.8 billion and $2.4 billion, respectively. LHRH agonist analogs are used to treat prostate cancer, postmenopausal breast cancer, etc., with global sales of approximately $4.8 billion. Other popular peptide drugs include teriparatide and linagliptin. In the Chinese market, sales of peptide drugs are also growing rapidly. They reached RMB 63.05 billion in 2017, mainly due to the large population base, accelerating aging, and a large number of cancer and chronic disease patients. The market demand for this will continue to expand, and there is still significant growth potential for peptide drugs. The peptide drug market is currently in a period of rapid development, and is expected to exceed $6 billion in the next 10 years. As synthetic technology advances and new indications are developed, peptide drugs will play an increasingly important role in the treatment of cancer, diabetes, and rare diseases.   In recent years, as the peptide drug market has continued to expand, demand for upstream raw materials has soared. Sirnaomics has accumulated years of experience in synthesis and modification technologies, and has mastered several core technologies, solving technical bottlenecks for the production of multiple peptide raw materials. Currently, its API products have been sold to countries and regions such as Europe, the United States, and South Korea, and it has established cooperative relationships with many well-known pharmaceutical enterprises at home and abroad.   In the future, Sirnaomics will continue to increase its R&D investment, enhance its peptide drug R&D capabilities and optimize production processes. It will also accelerate the implementation progress of its ongoing construction projects to seize market development opportunities. As its future capacity gradually releases, Sirnaomics is expected to drive sustained growth in its performance.

The study (NCT05138562) met its primary endpoint of change of dysmenorrhea (menstrual pain) score from baseline to 12 weeks compared to placebo across all tested doses (120 mg, 240 mg, and 320 mg) Merigolix is expected to emerge as a best-in-class treatment based on its excellent pain reduction and favorable safety profiles among gonadotropin-releasing hormone (GnRH) antagonists Positive results are also anticipated in ongoing clinical trials conducted in another disease such as uterine fibroids BOSTON and SEONGNAM, South Korea, May 8, 2024 /PRNewswire/ -- TiumBio Co., Ltd. (KOSDAQ: 321550), a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutics for patients with rare and incurable diseases, announced positive topline results from its Phase 2a clinical trial of Merigolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in patients with moderate to severe endometriosis-associated pain. The trial achieved its primary endpoint of reducing dysmenorrhea scores compared to placebo across all three dose groups, demonstrating a statistically significant difference (120mg group p=0.044, 240mg group p=0.001, 320mg group p<0.001). The study enrolled 86 female patients with moderate to severe endometriosis-associated pain across five European countries to evaluate the efficacy and safety of Merigolix in endometriosis. The patients were randomized to receive either Merigolix 120 mg, Merigolix 240 mg, Merigolix 320 mg, or a placebo once daily (QD) for 12 weeks. The change in endometriosis-associated pain from baseline to 12 weeks of treatment was assessed by measuring the mean dysmenorrhea score using the Numeric Rating Scale (NRS) over the past month. As a result of that, Merigolix achieved statistically significant and clinically meaningful improvements in mean dysmenorrhea scores from baseline compared to the placebo group at all tested doses: -4.3 point at the 120 mg dose (p=0.044), -5.4 point at the 240 mg dose (p=0.001), and -6.2 point at the 320 mg dose (p<0.001), while the placebo group reported -2.7 point. Merigolix was generally well tolerated, with no serious treatment-related adverse events, consistent with prior studies. The most commonly reported adverse events in the study population were hot flush, headache, and nausea. "Despite the small size of each group, with around 20 patients per group, Merigolix showed statistically significant efficacy compared to placebo at all doses in the Phase 2a clinical trial. This clinical trial confirmed that Merigolix achieved superior clinical outcomes in reducing dysmenorrhea and ensuring safety compared to other GnRH antagonists," said Hun-Taek Kim, Ph.D., MBA, CEO, TiumBio. "Now that this proof of concept study has supported potential for Merigolix, we aim to develop Merigolix into a best-in-class treatment for patients with endometriosis," he added. Likewise, a company official stated, "In addition to endometriosis, there is high potential to apply Merigolix to another women's disease such as uterine fibroids, and positive results are expected from ongoing clinical trials of Merigolix in China and Republic of Korea. Consequently, we anticipate that subsequent clinical development and business expansion of Merigolix will accelerate." Merigolix is an orally active non-peptide GnRH antagonist for the treatment of endometriosis and uterine fibroids. Merigolix offers improved convenience of administration and safety compared to conventional GnRH agonists. According to GlobalData, the endometriosis market will reach approximately $2.7 billion in 7 major countries (US, Germany, France, Italy, UK, Spain, Japan) by 2030. It is forecasted that GnRH antagonist therapies will replace existing treatments, accounting for about 70% of the total endometriosis market. About Endometriosis Endometriosis is a disorder in which the endometrial tissue that line the inside of the uterus grows out the uterus and is known to cause severe pelvic pain, menstrual pain, lower abdominal pain, and infertility which occurs in about 10-30% of women in childbearing age. It is estimated to affect approximately 200 million patients worldwide. About TiumBio Co., Ltd. TiumBio (Kosdaq: 321550) is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapeutics for patients with rare and incurable diseases. Its mission is to expand the hope and happiness of mankind through our science. TiumBio boasts three leading pipeline assets: Merigolix (code name: TU2670), TU2218, and TU7710, all in various stages of clinical development. Merigolix is a once-daily, oral GnRH receptor antagonist being developed for the treatment of endometriosis and uterine fibroids and is undergoing in global Phase 2 clinical trials. TU2218 is a first-in-class oral immune-oncology therapy targeting TGF-β and VEGF pathways to promote response rates in cancer patients when used in combination with immune checkpoint inhibitors. TU7710 is a novel recombinant FVIIa designed to extend its half-life in order to provide more clinical benefits to hemophilia patients with inhibitors. With its expertise in drug development, TiumBio is committed to the discovery and development of innovative treatments to ease the burden of debilitating diseases. For further information, visit our website at and connect with us on LinkedIn. Contacts: Junseok Jang, Head of Corporate Communications & Investor Relations [email protected] Suna Cho, Manager, Corporate Communications & Investor Relations [email protected] Da-ye Song, Manager, Corporate Communications & Investor Relations [email protected] SOURCE TiumBio